Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer.

Ridho AssidickyUnal Metin TokatIbrahim Oguzhan TarmanOzge SaatciPelin Gulizar ErsanUmar RazaHasan OgulYasser RiazalhosseiniTolga CanÖzgür Sahin

Published in: Breast cancer research and treatment (2022)

FN1 is central in chemoresistance. In chemoresistant tumors, hypoxia and resulting ECM stiffness repress the expression of the tumor suppressor miRNA, miR-326. Hence, re-expression of miR-326 or inhibition of its target ITGA5 reverses FN1-driven chemoresistance making them attractive therapeutic approaches to enhance chemotherapy response in TNBCs.

Keyphrases

long non coding rna
poor prognosis
cell proliferation
long noncoding rna
locally advanced
binding protein
cancer therapy
drug delivery